Business Context and Reporting Period
Company: SeaStar Medical Holding Corp (ICU)
Filing Type: Form 8-K (Current Report)
Date of Report: October 20, 2024
Reporting Period: The filing addresses a specific event occurring on October 20, 2024, regarding the resolution of a dispute with a former distributor.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels. The only specific financial figure disclosed is related to a settlement payment.
- Settlement Liability: $900,000 total.
- Payment Terms: Payable in three installments through December 31, 2024.
Material Changes
The filing reports the resolution of a legal and commercial dispute with Nuwellis, Inc., the Company's former exclusive distributor for its pediatric SCD product in the United States.
- Background: The Company terminated the Distribution Agreement effective August 18, 2024, citing a breach by Nuwellis. Nuwellis disputed this termination.
- Resolution: On October 20, 2024, the parties entered into a confidential settlement agreement and release.
- Outcome: The Company agreed to pay Nuwellis $900,000 to resolve the dispute.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of a settlement to end the dispute over the termination of the distribution agreement.
Risks and Contingencies:
- Financial Contingency: The Company has a near-term cash outflow obligation of $900,000 to be paid by year-end 2024.
- Operational Impact: The termination of the exclusive distribution agreement with Nuwellis may impact the sales and distribution of the pediatric SCD product in the U.S., though the filing does not detail replacement distribution arrangements.
Unusual Items: The $900,000 settlement payment is a non-recurring expense related to the legal dispute.
Investor Verification Checklist
- Verify the Company's current cash position to ensure it can meet the $900,000 settlement obligation by December 31, 2024.
- Confirm the status of the pediatric SCD product distribution in the U.S. following the termination of the Nuwellis agreement.
- Review the Company's most recent 10-Q or 10-K for baseline liquidity and working capital figures not included in this 8-K.
- Monitor for any future disclosures regarding the terms of the confidential settlement agreement if material details are later revealed.